In a randomized, double-blind, placebo-controlled study involving 120 male volunteers aged between 21 and 35 years, participants were arranged into three groups. Each group received a daily dose of either a placebo or 200 or 400 mg of LN18178 for a duration of 56 days. The primary focus of the study was to measure the potential increase in serum testosterone levels (both free and total). Secondary measures incorporated other hormones like dihydrotestosterone, cortisol, and Luteinizing hormone, as well as physical indicators such as hand grip strength and mid-upper arm circumference. Additionally, thorough checks were run pertaining to each participant's vital signs and clinical chemistry parameters in blood and urine to ensure product safety.

After the intervention, both dosage levels of LN18178 significantly raised free testosterone levels. The higher dose group also showed noteworthy increases in total testosterone and luteinizing hormone levels. Meanwhile, the other hormone changes were found to be statistically insignificant. More importantly, the LN18178-400 group displayed significant enhancements in their hand grip strength and mid-upper arm circumference post-trial. The completion of the trial saw participants' vital signs and hemato-biochemical parameters within the normal range, suggesting that LN18178 is both safe and tolerable.